公开(公告)号：US20240360248A1

公开(公告)日：2024-10-31

申请号：US18684078

申请日：2022-08-17

Applicant: NANOMAB TECHNOLOGY LIMITED

Inventor： Chung Lim WONG ,  Hong Hoi TING

IPC: C07K16/40 ,  G01N33/573 ,  G01N33/68

CPC classification number: C07K16/40 ,  G01N33/573 ,  G01N33/6854 ,  C07K2317/565 ,  C07K2317/569

Abstract: Provided are a set of specific single-domain antibody coding sequences targeting PTK7 and an application thereof. The provided anti-PTK7 single-domain antibody may effectively bind to a PTK7 antigen, which provides a basis for the research and development of drugs targeting PTK7, including radionuclide drug conjugates, antibody drug conjugates, multispecific antibody drugs and so on.

公开(公告)号：US20200276330A1

公开(公告)日：2020-09-03

申请号：US16647467

申请日：2018-09-13

Applicant: NANOMAB TECHNOLOGY LIMITED

Inventor： Hong Hoi TING ,  Chung Lim WONG

IPC: A61K47/68 ,  A61K51/08 ,  A61K49/16 ,  G01N33/68

Abstract: Disclosed is the use of a radiolabeled anti-nanobody in the prognosis and diagnosis of cancers. In particular, disclosed is an immunoconjugate for detecting a PD-L1 molecule. The immunoconjugate comprises the VHH chain of a specific anti-PD-L1 nanobody and a radionuclide, and can be used for non-invasive detecting of expression of the object PD-L1 to be detected. The immunoconjugate of the invention has small size and high specificity, and is suitable for systemic detection which simultaneously targets primary and metastatic tumors, and has high accuracy and low radiation dose.

公开(公告)号：US20240368302A1

公开(公告)日：2024-11-07

申请号：US18575754

申请日：2022-06-30

Applicant: Nanomab Technology Limited

Inventor： Chung Lim WONG ,  Hong Hoi TING

IPC: C07K16/30 ,  A61K47/68 ,  G01N33/574 ,  G01N33/68

Abstract: The application relates to the technical field of antibody drugs and provided are a group of sequences encoding a specific single-domain antibody for TROP2 and the use thereof. The provided anti-TROP2 single-domain antibody can effectively bind to a TROP2 antigen, and provides a basis for research and development of drugs targeting TROP2, including a nuclide-drug conjugate, an antibody-drug conjugate, a multispecific antibody drug, etc.